ClinicalTrials.gov
 Home    Search    Study Topics    Glossary  
 

  Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Screening for Primary Ciliary Dyskinesia Using Nasal Nitric Oxide

This study is not yet open for participant recruitment.
Verified by Ziv Hospital, August 2008

Sponsored by: Ziv Hospital
Information provided by: Ziv Hospital
ClinicalTrials.gov Identifier: NCT00739817
  Purpose

Background: Primary ciliary dyskinesia (PCD) is a rare genetic disease characterised by recurrent respiratory infections and subfertility due to dysfunction of cilia (brushes) of the lining cells. Undiagnosed and untreated it can result in an irreversible crippling chronic lung disease. The diagnosis of PCD is a difficult one and involves the complex assessment of ciliary structure and function. Thus, PCD is under diagnosed and appropriate preventative and symptomatic treatment may be denied in many patients. In addition, the gene responsible for PCD is at present unknown, thus preventing pre-natal diagnosis and genetic counseling.

Working hypothesis and aims: Recently, it has become apparent that the evaluation of nasally expired nitric oxide (NO) constitutes a simple and non-invasive diagnostic method, which discriminates between PCD patients, PCD carriers and healthy controls at high rate of specificity and sensitivity. Testing is simple and last approximately one minute. We have recently identified a unique isolated Druze population with high prevalence of PCD. The high frequency of disease places this closed community at a high risk of undiagnosed PCD.

The aim of this project is to use nasal NO measurement as a screening tool to identify possible undiagnosed cases of PCD and PCD carriers in this high risk Druze population.


Condition
Primary Ciliary Dyskinesia

Genetics Home Reference related topics:   familial paroxysmal nonkinesigenic dyskinesia   

ChemIDplus related topics:   Nitric oxide    Salicylsalicylic acid    Sodium salicylate   

U.S. FDA Resources

Study Type:   Observational
Study Design:   Other, Prospective
Official Title:   Screening for Primary Ciliary Dyskinesia Using Nasal Nitric Oxide

Further study details as provided by Ziv Hospital:

Primary Outcome Measures:
  • Nasal NO < 105 ppb [ Time Frame: at enrollment ] [ Designated as safety issue: No ]

Estimated Enrollment:   6000
Study Start Date:   July 2009

  Eligibility
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample

Study Population

community


Criteria

Inclusion Criteria:

  • Voluntary willing to participate

Exclusion Criteria:

  • Recent URTI
  • Steroids use 2 weeks prior to testing
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00739817

Contacts
Contact: Israel Amirav, MD     97246828712     amirav@012.net.il    

Locations
Israel
Pediatric Department, Ziv Medical Center     Not yet recruiting
      Safed, Israel
      Contact: Israel Amirav, MD     9726828712     amirav@012.net.il    

Sponsors and Collaborators
Ziv Hospital
  More Information


Responsible Party:   Ziv Medical center ( Israel Amirav )
Study ID Numbers:   HP-6-199-R
First Received:   August 21, 2008
Last Updated:   August 21, 2008
ClinicalTrials.gov Identifier:   NCT00739817
Health Authority:   Israel: Ministry of Health

Study placed in the following topic categories:
Otorhinolaryngologic Diseases
Heart Diseases
Primary ciliary dyskinesia
Cardiovascular Abnormalities
Bronchiectasis
Salicylsalicylic acid
Sodium Salicylate
Central Nervous System Diseases
Situs Inversus
Dyskinesias
Kartagener Syndrome
Dextrocardia
Nitric Oxide
Kartagener syndrome
Situs inversus viscerum
Signs and Symptoms
Respiratory Tract Diseases
Genetic Diseases, Inborn
Movement Disorders
Ciliary Motility Disorders
Neurologic Manifestations
Congenital Abnormalities
Heart Defects, Congenital

Additional relevant MeSH terms:
Respiratory System Agents
Vasodilator Agents
Respiratory System Abnormalities
Neurotransmitter Agents
Antioxidants
Molecular Mechanisms of Pharmacological Action
Bronchial Diseases
Nervous System Diseases
Physiological Effects of Drugs
Anti-Asthmatic Agents
Cardiovascular Agents
Protective Agents
Pharmacologic Actions
Autonomic Agents
Therapeutic Uses
Free Radical Scavengers
Endothelium-Dependent Relaxing Factors
Cardiovascular Diseases
Peripheral Nervous System Agents
Bronchodilator Agents

ClinicalTrials.gov processed this record on October 15, 2008




Links to all studies - primarily for crawlers